{"name":"Eyenovia Inc.","slug":"eyenovia-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxQNWxYdDRxWFBUSDU1a09kNFgwdDMwWlVmTkxseHVUcV9wR19iUXkwb2FoN2dmdVd1dkx5eGRmR1hsNGlOeWdmcDJ4NWxRbnBIQlRBZ3NYWGN1UnNDWVh2SnYtd2ZYVG1Jc1dxcDV3aGFLZGNUa2Z4ckdPeVFFTGt2S29saHRSMHIzTmFHbl9EdmZTMGlpekhPR3Jtcjl4aTBWRWU0bmRfZU03RkRZMDBiMGtVLUlEaWx1UHdBd1ByNFlhMWIwM0o4WkRnQWJteGpZYlc0RTVoYUNESUlxU0RIVTJKUzc2VDlpWGpVRkJQbHZxNWpic1BpNlU1RW1jU0lscVJLUzJkMTZQenZpMU9ZWXZZdFdOTFk?oc=5","date":"2025-06-12","type":"deal","source":"Ophthalmology Times","summary":"Formosa Pharmaceuticals grants Harrow commercial rights in US to clobetasol propionate ophthalmic suspension 0.05% (BYQLOVI), terminates deal with Eyenovia - Ophthalmology Times","headline":"Formosa Pharmaceuticals grants Harrow commercial rights in US to clobetasol propionate ophthalmic suspension 0.05% (BYQL","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxPbDVuYi1pUFFMbzlvSUxleXFiZGJHbVBkR3NPaEdLTHlDamszRmpEN00zbmNXdzI3b0k5RlllNEhReF94cENIRVVGTVBXOWxVNFZBajJ0ZXVsWkF1ZUh4cFhqSGxkVnF3cWxJNEtnMC1VOHlwQXRzVkNHcUh2QnY5ejdPR0ZmQmVBMUZPTHJEaVN0S21ZZ2VZbmVEbDRKT0xMNFhrbWlUVVZ6VjNid0hndjEybVk5T3ZkVElWcXZvWGFOTEZJN09TZUtfTzVGRDdxUllJ?oc=5","date":"2025-06-09","type":"deal","source":"Eyes On Eyecare","summary":"Harrow acquires U.S. rights to clobetasol propionate for postop inflammation and pain - Eyes On Eyecare","headline":"Harrow acquires U.S. rights to clobetasol propionate for postop inflammation and pain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQMDhMdU9EeDlVcFRMRlVDa1FaaUo4RkFKekpySFdodEZHUnoydVJrSVFNTGNNZzg0Rnp4X2g1TXBoWDJIOHA5aDFPU0lpOGM1SnRNd3pITU1zNUhCckpBQlJGVHF2NzhUR3VUVE5jMG83UVhKc2U5WHg4SURiV3JYMzc2REJJSXhRZ0hmUUhSbHhQcmdtTHVXYmQ4UUZuMTE1TjNKNGJVQ1dJN21kRWdFTEVGOC1zUQ?oc=5","date":"2025-03-28","type":"deal","source":"Eyes On Eyecare","summary":"Eyenovia proposes merger with Betaliq to form glaucoma company - Eyes On Eyecare","headline":"Eyenovia proposes merger with Betaliq to form glaucoma company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQUEo1NEpKLU1jRndnaDFGUEQ4Q2FmM2VaNEVjdUYxYV9VMVdNT0dYR3BjMTBadGR2UUJCVE8wU05OMi1SOXVJLURKYXNPUDRad0RILUZBUVhwZzRNOVo3YWtFVnIxQlB5LXJIWk1WRjlTdEFlRGdQYzg1NWtqeVdmNWtVNDlhZHgtZ1g5NVFmend3eDZHdElnbmN1YUExZ19XNzQ1TXRDLWFXMVJFemFSTmNmYXN5LTVWVlE?oc=5","date":"2024-11-15","type":"trial","source":"reuters.com","summary":"Eyenovia to end eye drug study, cut 50% of its workforce - reuters.com","headline":"Eyenovia to end eye drug study, cut 50% of its workforce","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQWXdTdXREWFJWS0ZrMTA3Y3ZjclNFRVVqWkF2VmJoY0hOMm1jZ0ZuSWZoekZnWFVzUWtJemRZSjhGNnJqUW1lR1JCWXV6NEhDSmk0V2tWX2YtMV82VERJLWFNVm5JQ2Vyd1cybEpDN09WSDRyVHhNUkwyck1YZGxydDZuNWNHY2pmbG5haDhRMkRnNDlncWJqam01aXNOcUtOb2YtSEEtQ1dzYVNsZ0lYYVhB?oc=5","date":"2024-09-09","type":"pipeline","source":"Nasdaq","summary":"Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization - Nasdaq","headline":"Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the Uni","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPZ0lkVThpR09HZjRGLXZpcmh0bjJaVVVOUGhEMmU2Nk9fR1gyQ05EZ2k4SzNLQi0zRndMV1ktcVd2YVhIWnBBckhyQWJ6WnduQlFPdmVyWVdPZjlXenNaeC0tcElGbXRhZl8zNDFCcDNsdy1lTnRDVDJrWS1lU0JvTWpSaXFiQUFNalRaU1pHTGtKNEdIVU9xVVU5Y3E3bW1aOXg0UmwzY0xtZ002WURvVE12Yw?oc=5","date":"2024-08-09","type":"deal","source":"BioSpectrum Asia","summary":"US-Taiwan partnership to develop treatment for dry eye disease - BioSpectrum Asia","headline":"US-Taiwan partnership to develop treatment for dry eye disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxNNWtwZWVKRTh5bkVUWFFGbG1haFdIOHdjZnRXMDE5T0hZVm50WUJyUmFRVWg3N3JaY2RKellFREltRC10VFBlcWtxUFl4cUhFUnF2Y1FFTHBfa29ueHRuc3Zza2dqdm5faGFRMEFzNnNXN0pZRXpsQ21LWTBlY3J1d2JHUlFRTHpmVmdBYlRkRDFXaHo5TFhqQ25YRmI2MU1adG82cHJNQ3JCWWpEeEM4TFVzSkVXcjBRdGd5b2xCYWJsZnFPM01qMThNVXVDMzUybUc2LUQwbkt2NmwzNV9FaklKbDFrZFVzMEx6a1dBTHM2TDJjT2s5Uk40dS0tZzVUcHROX0lFQzh4SENURzJpakY4RjljS0NQZC1jdUFVSzJVOWNkUU5IUG93?oc=5","date":"2024-08-07","type":"pipeline","source":"BioSpace","summary":"Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States - BioSpace","headline":"Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNTXc3RE05VUc5Y09aN2VDMXlNd215LXJSQ19sbENLV3ZBY0RCMFlPdlFjMXNTZFcyZ1cxd1FJT1hCbjdiWEVYc1BVOE1Td0VzcWl2cjl2M0R4eTRyMXJJdW5mSGEyS0J3QWNZRGRIbkRWdE5BTkJxSkRqc2FZbkRfWlFxNTNfcXVaX18xOVJRSjlfeUJQZjRneXUwbGozMUY4bUh1dGVPRDlraWQ4TDU3TjAxTnp4dFFp?oc=5","date":"2024-07-24","type":"deal","source":"Ophthalmology Times","summary":"Eyenovia, Inc. and Senju Pharmaceutical Co., Ltd. sign new collaboration agreement - Ophthalmology Times","headline":"Eyenovia, Inc. and Senju Pharmaceutical Co., Ltd. sign new collaboration agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPYWxRcmZYNG5Uei1XOE9LMnNrVm5wWks3M1JBY013Wm1DVERxMW5kWGpEWnhOX2ljRUkyMDVfa3MyR0ZNWEJUeG5tVXVSd2hCYnl0NmdmcW5kUVR3aHU4RXV2M2hvVVM2dU10VVN2ODJNNUlOZUVvRWw2RWQtZjlHUUJtcjlIemIya2dDc1FkNWl2c1ctbTU0SHdwbnRzVl9xVU41bUVhYThfMEZmeDdEQ1UyVk5pYjJDZzJ4Uw?oc=5","date":"2024-03-05","type":"regulatory","source":"Stock Titan","summary":"Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery -","headline":"Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNU3QyVkw3dFhTM0NvempMYTRwVXUwcVJsa0tLQmxkVXdCbnIwaXZCOE1YNUVPd2stSy1ZR3FncWgyQUxfSUc1ZDFUVC1KR1VQSlpLOHZueDBSNGMwSlVsM2FLQkdGU1o4U1E4dXQ1RkJqQUVuRjJrenpGV2pWXzIzNERxeE00Q0stR1BDc3hCSFJvVmNJTWJ1V1R1dWt6QU9BMmljR0JxNXlER0tSQ1JqdExSRHlhV0VNVGJqbVRkZmk0RmNV?oc=5","date":"2024-03-04","type":"regulatory","source":"reuters.com","summary":"US FDA approves Eyenovia's eye drug, Formosa Pharma says - reuters.com","headline":"US FDA approves Eyenovia's eye drug, Formosa Pharma says","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxOQ2F3S1FKWjZTdXN1QVFhQlZ3T0lyRkRocnB4QlM4UHJJVWxfM2xaZlRRUmxBd3VkTnk4RmZfZGJHS3dfbW1JOGwzVDZTeGJnNkRwNlh6VERTM2tTbDN3MjFlUC1ZN3habWZrd3Q0LVgwNFU2M1BTUTJQaUNhUXlna0Q5TVFxNmZJNlUwY09kQVpHcXVlaE5LS2NfVWNnRGdDMVlVb0drVFVHMzlfZHpyOGdnRkFNdi1WQ0t6RU1DZTJvc0xYTzhxWEdtTDVpXzYtUnNQYkhVdER3MVpLemdBaUJ3?oc=5","date":"2024-03-04","type":"regulatory","source":"modernretina.com","summary":"FDA approves clobetasol propionate ophthalmic suspension 0.05% from Formosa Pharmaceuticals and AimMax Therapeutics - modernretina.com","headline":"FDA approves clobetasol propionate ophthalmic suspension 0.05% from Formosa Pharmaceuticals and AimMax Therapeutics","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNTTJqdkRsbldsanRiMXhFZV9PZklwWEFJdjRSdDlybTJiZUZGNWNjMHBiaUR0NlhITWdSN3dBSDlTMHp3cnJFaFpaTmFtYlV4NkRPQXhzMTd1SkUwUDUzVlN5SlZrc1pENXNoV0hvek9qelRMM2x2azduVllXZUVCbjJ2S29JS1dKWUxfaC1OenVPQUpjMkdtTDhaVjY?oc=5","date":"2022-07-27","type":"pipeline","source":"citybiz","summary":"Eyenovia Appoints Michael Rowe as Chief Executive Officer - citybiz","headline":"Eyenovia Appoints Michael Rowe as Chief Executive Officer","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}